Advances in head and neck cancers on behalf of the French Intergroup ORL and GORTEC;Évolution des concepts dans les cancers des voies aérodigestives supérieures, sous l'égide de l'Intergroupe ORL (GORTEC, GETTEC, GERCOR)

Bulletin du Cancer

Volumn 100, Issue 10, 2013, Pages 983-997

  Thariat, J ^a   Jegoux, F ^a   Pointreau, Y ^a   Fayette, J ^a   Boisselier, P ^a   Blanchard, P ^a   Alfonsi, M ^a   Auperin A ^a   Bardet, E ^a   Bensadoun, R J ^a   Garaud, P ^a   Geoffrois, L ^a   Graff, P ^a   Guigay, J ^a   Janot, F ^a   Lapeyre, M ^a   Lefebvre, J L ^a   Martin, L ^a   Racadot, S ^a   Rolland, F ^a   Sire, C ^a   Tao, Y ^a   Tuchais, C ^a   Chibaudel, B ^a   Girard Calais, M H ^a   Cornely, A ^a   Vintonenko, N ^a   Calais, G ^a   De Raucourt, D ^a   Lacau Saint Guily, J ^a   Bourhis, J ^a   more..

^a Institut de Cancérologie de l'Ouest René Gauducheau ^*  (France)

Author keywords

Cancer; Chemotherapy; Head and neck; Radiation therapy; Surgery

Indexed keywords

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; FRANCE; HEAD AND NECK CANCER; HUMAN; MEDICAL SPECIALIST; ORGANIZATION; PROGRESSION FREE SURVIVAL;

EID: 84886821386     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2013.1829     Document Type: Article

References (41)

1. Remacle M, Hantzakos A, Eckel H, et al. Endoscopic supraglottic laryngectomy: a proposal for a classification by the working committee on nomenclature, European Laryngological Society. Eur Arch Otorhinolaryngol 2009; 266: 993-8.
2. Hartl DM, Ferlito A, Silver CE, et al. Minimally invasive techniques for head and neck malignancies: current indications, outcomes and future directions. Eur Arch Otorhinolaryngol 2011; 268: 1249-57.
3. Vergez S, Lallemant B, Ceruse P, et al. Initial multi-institutional experience with transoral robotic surgery. Otolaryngol Head Neck Surg 2012; 147: 475-81.
4. Lund VJ, Stammberger H, Nicolai P, et al. European position paper on endoscopic management of tumours of the nose, paranasal sinuses and skull base. Rhinol Suppl 2010; 22: 1-143.
5. Tao L, Lefevre M, Ricci S, et al. Detection of occult carcinomatous diffusion in lymph nodes from head and neck squamous cell carcinoma using real-time RT-PCR detection of cytokeratin 19 mRNA. Br J Cancer 2006; 94: 1164-9.
6. Thompson CF, St John MA, Lawson G, et al. Diagnostic value of sentinel lymph node biopsy in head and neck cancer: a meta-analysis. Eur Arch Otorhinolaryngol 2012; 270: 2115-22.
7. Jerjes W, Upile T, Hamdoon Z, et al. Photodynamic therapy outcome for T1/T2 N0 oral squamous cell carcinoma. Lasers Surg Med 2011; 43: 463-9.
8. Batra PS, Luong A, Kanowitz SJ, et al. Outcomes of minimally invasive endoscopic resection of anterior skull base neoplasms. Laryngoscope 2010; 120: 9-16.
9. Jegoux F, Bedfert C, Alno N, et al. Mandibular reconstruction for the treatment of oral carcinomas: state of the art and perspectives. Ann Otolaryngol Chir Cervicofac 2009; 126: 138-48.
10. Julieron M, Germain MA, Schwaab G, et al. Free bone flaps in esthetic and functional rehabilitation after segmental mandibulectomy. Apropos of 38 cases. Ann Otolaryngol Chir Cervicofac 1996; 113: 353-8.
11. Dequanter D, Lothaire P. The role of salvage surgery in organ preservation strategies in advanced head and neck cancer. B-ENT 2008; 4: 77-80.
12. Tan HK, Giger R, Auperin A, et al. Salvage surgery after concomitant chemoradiation in head and neck squamous cell carcinomas - stratification for postsalvage survival. Head Neck 2010; 32: 139-47.
13. Machtay M, Moughan J, Trotti A, et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 2008; 26: 3582-9.
14. Hamoir M, Ferlito A, Schmitz S, et al. The role of neck dissection in the setting of chemoradiation therapy for head and neck squamous cell carcinoma with advanced neck disease. Oral Oncol 2012; 48: 203-10.
15. Thariat J, Ang KK, Allen PK, et al. Prediction of neck dissection requirement after definitive radiotherapy for head-andneck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2012; 82: e367-374.
16. Thariat J, Hamoir M, Garrel R, et al. Management of the neck in the setting of definitive chemoradiation: is there a consensus? A GETTEC study. Ann Surg Oncol 2012; 19: 2311-9.
17. The Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991; 324: 1685-90.
18. Lefebvre JL, Chevalier D, Luboinski B, et al. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 1996; 88: 890-9.
19. Richard JM, Sancho-Garnier H, Pessey JJ, et al. Randomized trial of induction chemotherapy in larynx carcinoma. Oral Oncol 1998; 34: 224-8.
20. Forastiere AA, Zhang Q, Weber RS, et al. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 2012; 31: 845-52.
21. Pointreau Y, Garaud P, Chapet S, et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst 2009; 101: 498-506.
22. Blanchard P, Bourhis J, Lacas B, et al Meta-Analysis of Chemotherapy in Head and Neck Cancer, Induction Project, Collaborative Group. Taxane-Cisplatin-Fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group. J Clin Oncol 2013; 31: 2854-60.
23. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2011; 11: 21-8.
24. Lefebvre JL, Pointreau Y, Rolland F, et al. Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study. J Clin Oncol 2013; 31: 853-9.
25. Thariat J, Bensadoun RJ, Etienne-Grimaldi MC, et al. Contrasted outcomes to gefitinib on tumoral IGF1R expression in head and neck cancer patients receiving postoperative chemoradiation (GORTEC trial 2004-02). Clin Cancer Res 2012; 18: 5123-33.
26. Pignon JP, le Maître A, Maillard E, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. MACH-NC Collaborative Group. Radiother Oncol 2009; 92: 4-14.
27. Lorch JH, Goloubeva O, Haddad RI, et al. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol 2011; 12: 153-9.
28. Haddad R, O'Neill A, Rabinowits G, et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol 2013; 14: 257-64.
29. Bourhis J, Overgaard J, Audry H, et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 2006; 368: 843-54.
30. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008; 100: 261-9.
31. Nutting CM, Morden JP, Harrington KJ, et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol 2011; 12: 127-36.
32. Toledano I, Graff P, Serre A, et al. Intensity-modulated radiotherapy in head and neck cancer: results of the prospective study GORTEC 2004-03. Radiother Oncol 2012; 103: 57-62.
33. Graff P, Lapeyre M, Desandes E, et al. Impact of intensitymodulated radiotherapy on health-related quality of life for head and neck cancer patients: matched-pair comparison with conventional radiotherapy. Int J Radiat Oncol Biol Phys 2007; 67: 1309-17.
34. Janot F, de Raucourt D, Benhamou E, et al. Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. J Clin Oncol 2008; 26: 5518-23.
35. Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007; 357: 1695-704.
36. Burtness B, Goldwasser MA, Flood W, et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005; 23: 8646-54.
37. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359: 1116-27.
38. Ravasco P, Monteiro-Grillo I, Vidal PM, Camilo ME. Cancer: disease and nutrition are key determinants of patients' quality of life. Support Care Cancer 2004; 12: 246-52.
39. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003; 362: 1255-60.
40. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363: 24-35.
41. Pajares B. Human papillomavirus (HPV)-related head and neck squamous cell carcinoma (HNSCC) and outcome after treatment with epidermal growth factor receptor inhibitors (EGFR inhib) plus radiotherapy (RT) versus conventional chemotherapy CT) plus RT. J Clin Oncol 2011; 29: 5528.